Mediapharma s.r.l., an italian spin-off supported by INNOVA's seed capital company, INVENT s.a.s, successfully brings the results of 20 years of research on monoclonal antibodies to the pharmaceutical market, a breakthrough for the diagnosis and cancer treatment.
Listen to the interview of Professor Iacobelli transmitted on RAI3 Leonardo News on 25-01-2010 (in italian):
